

ICMJE DISCLOSURE FORM

Date: April 8, 2022

Your Name: Eziafa Oduah

Manuscript Title: The Emerging Landscape of EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma – Successes and Challenges

Manuscript number (if known): JTD-22-432

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

I have no conflicts of interests as it pertains to this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: April 8, 2022

Your Name: Chung-Shien Lee

Manuscript Title: The Emerging Landscape of EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma – Successes and Challenges

Manuscript number (if known): JTD-22-432

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>None</u>	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>None</u>	
3	Royalties or licenses	<u>None</u>	
4	Consulting fees	<u>Consultant</u>	Pharmacy Times, Annenberg, Health First, Amida Care

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ Honoraria for lectures	Identification of ALK and ROS1 Biomarkers and Appropriate Treatment in the Management of Non-Small Cell Lung Cancer (Pharmacy Times)
			Targeting Lung Cancer with a Focus (American College of Clinical Pharmacy)
			Evaluating The Starting Dose of Tyrosine Kinase Inhibitors In Solid Tumors, Do We Have It Right? (HOPA Annual Conference)
			HOPA Mentorship Program Update
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ Advisory board participation	G1 Therapeutics, Takeda
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ Leadership positions	Member, HOPA Publication committee
			President, Long Island Society of Health-System Pharmacists
			Chair, NYSCHP Education and Professional Development Committee
			Chari, NYSCHP Oncology Symposium
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

Dr. Lee reports consulting fees from Pharmacy Times, Annenberg, Health First and Amida Care. Dr. Lee reports honoraria for lectures from Pharmacy Times, American College of Clinical Pharmacy, HOPA Annual Conference and HOPA Mentorship Program Update. Dr. Lee serves on the advisory board of G1 Therapeutics and Takeda. Dr. Lee serves as member of HOPA Publication Committee, President of Long Island Society of Health-System Pharmacists, Chair of NYSCHP Education and Professional Development Committee, and Chair of NYSCHP Oncology Symposium. Dr. Lee has no conflicts of interests as it pertains to this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: April 8, 2022

Your Name: Nagarashee Seetharamu

Manuscript Title: The Emerging Landscape of EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma – Successes and Challenges

Manuscript number (if known): JTD-22-432

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	-None	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	Honoraria for lectures	OnLive Thoracic oncology updates- institutional perspectives 2020

	manuscript writing or educational events		
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Advisory board participation	Amgen, AstraZeneca, Blueprint pharma, Takeda, Regeneron, Merck, Genentech, Boehringer Ingram
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ Leadership positions	Member, Alliance Oncology Preventions Committee Member, Alliance Oncology Respiratory Committee IASLC, publications committee ASCO, virtual mentorship committee
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

Dr. Seetharamu reports honoraria for lectures sponsored by OncoLive and Total Health Conferencing. Dr. Seetharamu serves on the advisory board of AstraZeneca, Blueprint pharma, Takeda, Regeneron, Merck, Genentech, Boehringer Ingram and Mirati. Dr. Seetharamu serves as a member of Alliance Oncology Preventions Committee, member of Alliance Oncology Respiratory Committee, publications committee of IASLC and virtual mentorship committee of ASCO. Dr. Seetharamu has no conflicts of interests as it pertains to this manuscript.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.